15.097 articles found

14-3-3 binding maintains the Parkinson's associated kinase LRRK2 in an inactive state.

Martinez Fiesco JA, Beilina A, Alvarez de la Cruz A, Li N, Metcalfe RD, Cookson MR, Zhang P.

Nat Commun · 2025-08-05

DOI: 10.1038/s41467-025-62337-1PMID: 40764514

Utilization of Skin Punch Biopsy for the Diagnosis of α-Synucleinopathy in Clinical Practice.

Gummerson CE, Tinaz S, Santini V, Zubair A.

Mov Disord Clin Pract · 2025-08-05

DOI: 10.1002/mdc3.70272PMID: 40762364

Derailed degradation: LRRK2-dependent exocytosis in Parkinson's disease.

Ferguson SM.

Proc Natl Acad Sci U S A · 2025-08-04

DOI: 10.1073/pnas.2515758122PMID: 40758897

Elevated plasma levels of alpha-synuclein are dispensable for Parkinson's disease pathology.

Jeong JY, Kim N, Li Y, Kim DJ, Kim HK, Oh WJ.

NPJ Parkinsons Dis · 2025-08-04

DOI: 10.1038/s41531-025-01091-zPMID: 40759658

Cardiac 123I-Meta-Iodobenzylguanidine Imaging as a Biomarker for Body-First Parkinson's Disease: Linking Peripheral α-Synuclein to Clinical Subtyping.

Ryu DW, Yoo SW, Oh Y, Kim JS.

J Mov Disord · 2025-08-04

DOI: 10.14802/jmd.25137PMID: 40754311

Astrocytic Ceruloplasmin Deficiency Triggers Iron Toxicity and Neurodegeneration in a LRRK2 Parkinson’s Tri-Culture Model

Testa V, Montero-Muñoz J, Baruffi V, Alzeer M, Mularoni L, Fernández-Carasa I, Simmini G, Comellas-Comaposada N, Ake FA, Richaud Y, Weissleder C, Amengual J, Fabregat I, Deleidi M, Plass M, Pluchino S, Raya A, Consiglio A.

· 2025-08-02

DOI: 10.1101/2025.08.01.668099

Classification of GBA1 variants and their impact on Parkinson's disease: an in silico score analysis.

Lanore A, Tesson C, Basset A, Lejeune FX, Cogan G, Mangone G, Sambin S, Bertille N, Anheim M, Arnulf I, Ansquer S, Brandel JP, Brefel-Courbon C, Defebvre L, Drapier S, Eusebsio A, Fabbri M, Giordana C, Hainque E, Lehericy S, Marques A, Moreau C, Moro E, Ory F, Rolland AS, Thobois S, Vidailhet M, Devos D, Mariani LL, Lesage S, Brice A, Corvol JC, Predistim study group, Iceberg study group, NSPark study group.

NPJ Parkinsons Dis · 2025-08-02

DOI: 10.1038/s41531-025-01060-6PMID: 40753162

Pyridoxal phosphate inhibits alpha-synuclein-induced ferroptosis by activating GOT1 to enhance the methionine salvage pathway in Parkinson's disease.

Min X, Du Z, Wei J, Yuan Z, She Y, Jin X, Su Z, Mao H, Cai J, Zhu Z, He X.

Exp Neurol · 2025-08-02

DOI: 10.1016/j.expneurol.2025.115411PMID: 40752725

Inhibition of de novo ceramide synthesis mitigates alpha-synuclein pathology and restores cognitive function in a Parkinson's disease mouse model

Oh C, Lee E, Park M, Park M, Kim N, Wei S, Hwang N, Ryu D, Park D, Lee G.

· 2025-08-01

DOI: 10.21203/rs.3.rs-7167930/v1

Sex-specific vulnerability to behavioural and morphological alterations in a mouse model of Parkinson’s disease overexpressing mutant A53T alpha-synuclein

Zubelzu M, Bidgood R, Murueta-Goyena A, Ruiz-Ortega J, Lafuente J, Morera-Herreras T.

· 2025-08-01

DOI: 10.1101/2025.07.30.667616

Elevated phosphorylated α-synuclein and phosphorylated tau in Lrrk2 p.G2019S-mutant mice following influenza A pneumonitis

Lunn MO, Thakur K, Thakur K, Lengacher NA, Hake-Volling Q, aSCENT-PD Investigators, Tomlinson JJ, Sad S, Brown EG, Schlossmacher MG.

· 2025-08-01

DOI: 10.1101/2025.07.31.667659

Mechanism of flavonoid myricetin modulated aggregation in α-Synuclein and its familial mutants E46K and A30P

Tinku, Prajapati AK, Sahoo S, Deepak G, Nair S, Choudhary S.

Archives of Biochemistry and Biophysics · 2025-08-01